High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 101–200 of 1,000
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Chanan-Khan, A. A., & Giralt, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4250 · Cited by 195
Turesson, I., Velez, R., Kristinsson, S. Y., & Landgren, O. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4177 · Cited by 195
Shi, J., Tricot, G., Szmania, S., Rosen, N., Garg, T. K., Malaviarachchi, P. A., Moreno, A., DuPont, B., Hsu, K. C., Baxter‐Lowe, L. A., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07340.x · Cited by 194
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Harousseau, J.-L., & Moreau, P. (2009) · New England Journal of Medicine · doi:10.1056/nejmct0805626 · Cited by 186
van Rhee, F., Szmania, S. M., Zhan, F., Gupta, S. K., Pomtree, M., Lin, P., Batchu, R. B., Moreno, A., Spagnoli, G., Shaughnessy, J., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3707 · Cited by 194
Sirohi, B., & Powles, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15736-x · Cited by 181
Turesson, I., Bjorkholm, M., Blimark, C. H., Kristinsson, S., Velez, R., & Landgren, O. (2018) · European Journal of Haematology · doi:10.1111/ejh.13083 · Cited by 174
Kastritis, E., Zervas, K., Symeonidis, A., Terpos, E., Delimbassi, S., Anagnostopoulos, N., Michali, E., Zomas, A., Katodritou, E., Gika, D., et al. (2009) · Leukemia · doi:10.1038/leu.2008.402 · Cited by 187
Björkstrand, B., Iacobelli, S., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Musto, P., Beksac, M., Bosi, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7312 · Cited by 182
“HDT with autologous stem-cell transplantation (ASCT) is part of the first-line standard treatment in patients up to the age of 65 years on the basis of the results of randomized trials.(3,4) Allogeneic stem-cell transplantation (alloSCT) with myeloablative conditioning has been used in myeloma since the mid1980s,(5) b…”
BackgroundSarasquete, M. E., García‐Sánz, R., González, D., Martínez‐López, J., Mateo, G., Martínez, P., Ribera, J., Hernández, J. M., Lahuerta, J. J., Órfão, A., et al. (2005) · PubMed · Cited by 196
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., et al. (2007) · Blood · doi:10.1182/blood-2006-08-042275 · Cited by 182
“During the last 10 years, high-dose melphalan with hemopoietic stem-cell support was the only option that significantly increased the rate of complete response (CR) and extended event-free and overall survival.(3,4) Oral low-dose melphalan in elderly patients and high-dose melphalan in younger patients therefore becam…”
BackgroundCavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, M., Vivo, A. D., Palareti, G., et al. (2004) · PubMed · Cited by 191
van Rhee, F., Szmania, S. M., Dillon, M., van Abbema, A. M., Li, X., Stone, M. K., Garg, T. K., Shi, J., Moreno-Bost, A. M., Yun, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0483 · Cited by 176
Primary Malignant Tumors of the Spine
Sundaresan, N., Rosen, G., & Boriani, S. (2009) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2008.10.004 · Cited by 173
Neben, K., Jauch, A., Bertsch, U., Heiss, C., Hielscher, T., Seckinger, A., Mors, T., Muller, N. Z., Hillengass, J., Raab, M. S., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016436 · Cited by 173
AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy
Cheung, M. C., Pantanowitz, L., & Dezube, B. J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-412 · Cited by 172
“Currently, high-dose chemotherapy with autologous stem cell transplant is the standard of care in HIV-negative patients [150, 151 ].”
BackgroundRoussel, M., Moreau, P., Huynh, A., Mary, J.-Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-229658 · Cited by 171
“Median duration of mucositis, d (range) 9 (2-13)”
BackgroundMinnie, S. A., Kuns, R. D., Gartlan, K. H., Zhang, P., Wilkinson, A. N., Samson, L., Guillerey, C., Engwerda, C., MacDonald, K. P. A., Smyth, M. J., et al. (2018) · Blood · doi:10.1182/blood-2018-01-825240 · Cited by 169
Popat, U., Saliba, R., Thandi, R., Hosing, C., Qazilbash, M., Anderlini, P., Shpall, E., McMannis, J., Körbling, M., Alousi, A., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.02.011 · Cited by 169
“5 (38–76) Sex Men 185 (61) Women 117 (39) Isotype IgG 177 (59) IgA 63 (21) Light chain only 47 (15) Other (IgD, IgM, Nonsecretory) 15 (5) Durie-Salmon stage at diagnosis I 59 (20) II 127 (42) III 103 (34) Unknown 13 (4) No.”
BackgroundRapoport, A. P., Aqui, N. A., Stadtmauer, E. A., Vogl, D. T., Fang, H.-B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G., et al. (2011) · Blood · doi:10.1182/blood-2010-08-299396 · Cited by 163
Harousseau, J.-L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1060 · Cited by 164
Advances in stem cell mobilization
Hopman, R. K., & DiPersio, J. F. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.01.001 · Cited by 161
Mitsiades, C. S., Mitsiades, N., Munshi, N. C., & Anderson, K. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.020 · Cited by 166
Sanchorawala, V., Skinner, M., Quillen, K., Finn, K. T., Doros, G., & Seldin, D. C. (2007) · Blood · doi:10.1182/blood-2007-07-099481 · Cited by 166
Shaughnessy, J. (2005) · Hematology · doi:10.1080/10245330512331390140 · Cited by 159
Dhakal, B., Szabo, A., Chhabra, S., Hamadani, M., D’Souza, A., Usmani, S. Z., Sieracki, R., Gyawali, B., Jackson, J. L., Asimakopoulos, F., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4600 · Cited by 159
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
Korbet, S. M., & Schwartz, M. M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020139 · Cited by 169
Advances in stem cell mobilization
Motabi, I. H., & DiPersio, J. F. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.09.003 · Cited by 160
“dose chemotherapy [1–5].”
Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Navarro Coy, N., Cook, G., Feyler, S., Johnson, P. R. E., Rudin, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043372 · Cited by 160
“It has previously been shown that the addition of cyclophosphamide to VAMP (vincristine, doxorubicin, and methylprednisone), a regimen very similar to VAD, increases response rates.(2,16) Having developed an oral induction regimen comprising cyclophosphamide, thalidomide, and dexamethasone (CTD),(17,18) we compared it…”
BackgroundResultSelf-citationRichardson, P. G., Mitsiades, C., Schlossman, R., Munshi, N., & Anderson, K. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 156
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 159
Sherman, A. C., Simonton, S., Latif, U., Spohn, R., & Tricot, G. (2005) · Journal of Behavioral Medicine · doi:10.1007/s10865-005-9006-7 · Cited by 153
“…in tumor stage (which in myeloma is classified as stage I-III, using the Durie and Salmon criteria, 1977) and prognostic status (e.g., beta 2 microglobulin, which is one of several markers associated with survival; Barlogie et al., 2004; Child et al., 2003) (see Table I for sample characteristics).”
BackgroundBarlogie, B., Attal, M., Crowley, J., van Rhee, F., Szymonifka, J., Moreau, P., Durie, B. G. M., & Harousseau, J.-L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6081 · Cited by 154
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2009.n.056 · Cited by 151
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Cook, G., Williams, C. D., Brown, J. M., Cairns, D. A., Cavenagh, J. D., Snowden, J. A., Ashcroft, A. J., Fletcher, M., Parrish, C., Yong, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70245-1 · Cited by 167
Self-citationTrends in survival of patients with primary plasma cell leukemia: a population-based analysis
Gonsalves, W. I., Rajkumar, S. V., Go, R. S., Dispenzieri, A. A., Gupta, V. K., Singh, P. P., Buadi, F. K., Lacy, M. Q., Kapoor, P., Dingli, D., et al. (2014) · Blood · doi:10.1182/blood-2014-03-565051 · Cited by 160
Sung, B., Kunnumakkara, A. B., Sethi, G., Anand, P., Guha, S., & Aggarwal, B. B. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0905 · Cited by 159
Cook, G., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Brown, J. M., Cavenagh, J. D., Snowden, J. A., Parrish, C., Yong, K., Cavet, J., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30049-7 · Cited by 147
Self-citationLacy, M. Q., Gertz, M. A., Dispenzieri, A. A., Hayman, S. R., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S. K., Greipp, P. R., Fonseca, R., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1179 · Cited by 151
Kumar, S., Witzig, T. E., Timm, M., Haug, J., Wellik, L., Kimlinger, T. K., Greipp, P. R., & Rajkumar, S. V. (2004) · Blood · doi:10.1182/blood-2003-11-3811 · Cited by 148
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Phekoo, K. J., Schey, S., Richards, M. A., Bevan, D. H., Bell, S., Gillett, D., & Møller, H. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05207.x · Cited by 151
“The Medical Research Council (MRC) Myeloma VII study (Child et al, 2003) reported an overall survival of 48Æ5 months for patients aged less than 65 years, which compares with the 42 months reported in this study.”
MethodResultSelf-citationThe inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S.-B., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 142
Costa, L. J., Alexander, E. T., Hogan, K. R., Schaub, C., Fouts, T. V., & Stuart, R. K. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.78 · Cited by 146
Mellqvist, U.-H., Gimsing, P., Hjertner, O., Lenhoff, S., Laane, E., Remes, K., Steingrimsdottir, H., Abildgaard, N., Ahlberg, L., Blimark, C., et al. (2013) · Blood · doi:10.1182/blood-2012-11-464503 · Cited by 139
Approach to the treatment of multiple myeloma: a clash of philosophies
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011) · Blood · doi:10.1182/blood-2011-06-297853 · Cited by 137
Gonsalves, W. I., Rajkumar, S. V., Gupta, V. A., Morice, W. G., Timm, M., Singh, P. P., Dispenzieri, A. A., Buadi, F. K., Lacy, M. Q., Kapoor, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.98 · Cited by 146
Barlogie, B., Tricot, G. J. K., Rasmussen, E., Anaissie, E. J., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K. A., Pineda‐Roman, M., Shaughnessy, J. D., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4084 · Cited by 141
“Total therapy 1 Enrollment 231 100 0 0 0 0 None NA NA Induction 231 100 8 6 8 (6) 14 None 145 (63) 27 (12) First transplantation 195 84 9 9 2 (2) 10 None 175 (76) 60 (26) Second transplantation 165 71 16 2 6 (3) 13 None 188 (81) 84 (36) Maintenance 128 55 0 83 15 (2) 21 None 189 (82) 94 (41) Total therapy 2, no thalid…”
Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
Bahlis, N. J., & Lazarus, H. M. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705395 · Cited by 144
How I treat multiple myeloma in younger patients
Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood · doi:10.1182/blood-2009-07-204651 · Cited by 133
Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies
Moreau, P., Avet-Loiseau, H., Harousseau, J.-L., & Attal, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5878 · Cited by 132
“These results were confirmed 7 years later by the British group (Medical Research Council [MRC] VII trial) in a larger cohort involving 400 patients.(8) As a consequence of these two studies, ASCT became the standard of care for frontline therapy, at least in younger patients ( 65 years of age) with normal renal funct…”
ResultDurie, B. G. M., Jacobson, J. L., Barlogie, B., & Crowley, J. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.111 · Cited by 132
Kapoor, P., Kumar, S., Fonseca, R., Lacy, M. Q., Witzig, T. E., Hayman, S. R., Dispenzieri, A., Buadi, F., Bergsagel, P. L., Gertz, M. A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-202010 · Cited by 132
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
Bladé, J., Rosiñol, L., Cibeira, M. T., Rovira, M., & Carreras, E. (2010) · Blood · doi:10.1182/blood-2009-08-238196 · Cited by 138
“Five trials comparing ASCT versus conventional chemotherapy have been fully published (Table 2) (23-27).”
BackgroundResultLing, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043331 · Cited by 130
“Median survival time is 4 to 5 years [2-4].”
BackgroundDuarte, R. F., Shaw, B. E., Marín, P., Kottaridis, P. D., Ortiz, M., Morante, C., Delgado, J., Gayoso, J., Goterriz, R., Martínez‐Chamorro, C., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.54 · Cited by 130
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Dimopoulos, M. A., Anagnostopoulos, A., & Weber, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.200 · Cited by 130
Kumar, S. K., Dingli, D., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · American Journal of Hematology · doi:10.1002/ajh.21191 · Cited by 132
“Prior to the introduction of these new drugs, randomized controlled trials had demonstrated a survival advantage for patients undergoing high dose therapy and autologous stem cell transplantation [5,6].”
BackgroundFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
“Although patients who receive a stem cell transplant and maintenance therapy have superior outcomes compared with those who are transplant ineligible [4, 5], both groups of patients frequently experience disease relapse and require subsequent lines of therapy (LOTs).”
BackgroundHaynes, R., Read, S., Collins, G. P., Darby, S. C., & Winearls, C. G. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp488 · Cited by 129
Murphy, S. V., & Atala, A. (2012) · BioEssays · doi:10.1002/bies.201200062 · Cited by 141
Stiff, P. J., Micallef, I. N., Nademanee, A. P., Stadtmauer, E. A., Maziarz, R. T., Bolwell, B. J., Bridger, G. J., Marulkar, S., Hsu, F. J., & DiPersio, J. F. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.11.021 · Cited by 142
“021 with conventional chemotherapy in randomized trials of patients with hematologic malignancies such as non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) [1-5].”
BackgroundShah, N., Callander, N. S., Ganguly, S., Gul, Z., Hamadani, M., Costa, L. J., Sengsayadeth, S. M., Abidi, M. H., Hari, P., Mohty, M., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.03.002 · Cited by 140
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Saad, A. A., Lima, M. J. G. D., Anand, S. M., Bhatt, V. R., Bookout, R., Chen, G. L., Couriel, D. R., Stasi, A. D., El-Jawahri, A. R., Giralt, S., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0021 · Cited by 139
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
Knudsen, L. M., Nielsen, B., Gimsing, P., & Geisler, C. H. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00446.x · Cited by 129
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 127
“thrombocytopenia,† days (range) 9 (2-19) 10 (2-20) NS”
RetractedGullà, A., Di Martino, M. T., Gallo Cantafio, M. E., Morelli, E., Amodio, N., Botta, C., Pitari, M. R., Lio, S. G., Britti, D., Stamato, M. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0489 · Cited by 120
“Presently its therapeutic value is in younger patients who undergo high-dose melphalan prior to autologous stem cell transplantation, as well as in nontransplant candidates or elderly patients as a part of first-line combination regimens (10, 11).”
BackgroundMoreau, P., Attal, M., Pégourié, B., Planche, L., Hulin, C., Facon, T., Stoppa, A.-M., Fuzibet, J.-G., Grosbois, B., Doyen, C., et al. (2011) · Blood · doi:10.1182/blood-2010-08-300863 · Cited by 123
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
Palumbo, A., Gay, F., Bringhen, S., Falcone, A. P., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn018 · Cited by 128
“CR or VGPR are considered important surrogates for remission duration and survival [19–22].”
BackgroundKumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Buadi, F. K., Hayman, S. R., Dingli, D., Gay, F., Sinha, S., Leung, N., Hogan, W. J., et al. (2011) · Cancer · doi:10.1002/cncr.26422 · Cited by 127
“Median bone marrow plasma cells (range), % 43 (2-90) 40 (1-80) NS”
BackgroundAuner, H. W., Szydlo, R., Hoek, J., Goldschmidt, H., Stoppa, A., Morgan, G. J., Moreau, P., Attal, M., Marit, G., Russell, N. H., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.255 · Cited by 127
Self-citationSaad, A. A., Mahindra, A. K., Zhang, M., Zhong, X., Costa, L. J., Dispenzieri, A. A., Drobyski, W. R., Freytes, C. O., Gale, R. P., Gasparetto, C., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.12.557 · Cited by 129
Giaccone, L., Storer, B. E., Patriarca, F. F., Rotta, M., Sorasio, R., Allione, B., Carnevale‐Schianca, F., Festuccia, M. B., Brunello, L., Omedè, P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-339945 · Cited by 129
“Autologous transplantation has been regarded as the standard of care for young myeloma patients.(1) Recently, “new drugs” such as lenalidomide and bortezomib have prolonged survival.”
BackgroundFifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
Bayraktar, U. D., Bashir, Q., Qazilbash, M., Champlin, R. E., & Ciurea, S. O. (2013) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.08.011 · Cited by 119
“Additionally, FM regimen with alemtuzumab was found to be effective in advanced CLL patients, with relatively low toxicity and a PFS of 45% at 2 years(140).”
BackgroundMethodInfluentialGonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Khan, A. A. C., Dingli, D., Dispenzieri, A. A., Fonseca, R., Hayman, S. R., Kapoor, P., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0264-8 · Cited by 130
Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N., Ackermann, J., Küenburg, E., Wieser, R., Zielinski, C. C., & Drach, J. W. (2006) · Leukemia · doi:10.1038/sj.leu.2404459 · Cited by 121
Zervas, K., Dimopoulos, M. A., Hatzicharissi, E., Anagnostopoulos, Α., Papaioannou, M., Mitsouli, C., Panagiotidis, P., Korantzis, J., Tzilianos, M., & Maniatis, A. G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh026 · Cited by 126
“survival compared to conventional chemotherapy alone [9, 10].”
Gimsing, P., Carlson, K. E., Turesson, I., Fayers, P. M., Waage, A., Vangsted, A. J., Mylin, A. K., Gluud, C. N., Juliusson, G., Gregersen, H., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70198-4 · Cited by 120
The impact of extramedullary disease at presentation on the outcome of myeloma
Wu, P., Davies, F. E., Boyd, K. D., Thomas, K., Dines, S., Saso, R. M., Potter, M. N., Ethell, M. E., Shaw, B. E., & Morgan, G. J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802657751 · Cited by 120
Self-citationBortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
Wang, M., Giralt, S., Delasalle, K., Handy, B., & Alexanian, R. (2007) · Hematology · doi:10.1080/10245330701214236 · Cited by 113
“The wider application of intensive therapy supported by autologous stem cells has improved the frequencies and durations of partial and complete remission for many patients with consequent longer survival [7-10] .”
BackgroundResultGertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Ansell, S. M., Elliott, M. A., Gastineau, D. A., Inwards, D. J., Micallef, I. N., Porrata, L. F., Tefferi, A., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704691 · Cited by 113
Rosiñol, L., Oriol, A., Mateos, M., Sureda, A. M., García-Sánchez, P., Gutierrez, N. C., Alegre, A. M., Lahuerta, J. J., de la Rubia, J., Herrero, C. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3323 · Cited by 117
Costa, L. J., Zhang, M., Zhong, X., Dispenzieri, A. A., Lonial, S., Krishnan, A. Y., Freytes, C. O., Vesole, D. H., Gale, R. P., Anderson, K. C., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.08.002 · Cited by 114
“001 Year of transplant 1995 49 (7) --1996 90 (13) --1997 186 (27) --1998 173 (25) --1999 188 (27) --2000 -- 213 (14) -2001 -- 314 (21) -2002 -- 292 (20) -2003 -- 218 (15) -2004 -- 427 (30) -2005 --- 547 (25) 2006 --- 531 (24) 2007 --- 318 (14) 2008 --- 579 (26) 2009 --- 169 (8)”
Zhang, L., Pan, L., Xiang, B., Zhu, H., Wu, Y., Chen, M., Guan, P., Zou, X., Valencia, C. A., Dong, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9021 · Cited by 117
“Conventional therapies such as hematopoietic stem cell transplantation, which mainly focused on myeloma cells, result in a low complete remission (CR) rate and short survival time in MM [2].”
BackgroundOutcome disparities in multiple myeloma: a SEER ‐based comparative analysis of ethnic subgroups
Ailawadhi, S., Aldoss, I. T., Yang, D., Razavi, P., Cozen, W., Sher, T., & Chanan-Khan, A. A. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09124.x · Cited by 124
“These were based on using 1995 for widespread utilization of ASCT for MM treatment (Vesole et al, 1994; Attal et al, 1996; Fermand et al, 1998; Child et al, 2003). and 2003 for the availability of novel therapeutic agents (proteasome inhibitors, immunomodulatory drugs) beyond clinical trial setting…”
MethodLahuerta, J. J., Mateos, M. V., Martínez‐López, J., Grande, C., de la Rubia, J., Rosiñol, L., Sureda, A. M., García‐Laraña, J., Díaz-Mediavilla, J., Hernández‐Garcia, M. T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.028027 · Cited by 118
“compared with conventional chemotherapy(1, 2).”
Sherman, A. C., Simonton, S., Latif, U., Plante, T. G., & Anaissie, E. J. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.09.023 · Cited by 110
“023 has become a front-line treatment for myeloma [1-3].”
O’Shea, D., Giles, C. M., Terpos, E., Perz, J. B., Politou, M., Sana, V., Naresh, K. N., Lampert, I. A., Samson, D., Narat, S., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705307 · Cited by 113
Salvage Second Hematopoietic Cell Transplantation in Myeloma
Michaelis, L. C., Saad, A. A., Zhong, X., Le‐Rademacher, J. G., Freytes, C. O., Marks, D. I., Lazarus, H. M., Bird, J. M., Holmberg, L., Kamble, R. T., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.01.004 · Cited by 110
“Pivotal studies from the 1990s and 2000s demonstrated prolonged remission and survival when AHCT was compared with chemotherapy alone [1-3].”
BackgroundMikhael, J. R., Belch, A. R., Prince, H. M., Lucio, M. N., Maiolino, A., Corso, A., Petrucci, M. T., Musto, P., Komarnicki, M., & Stewart, A. K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07409.x · Cited by 108
“%) of the 635 responseevaluable patients had received prior SCT.”
BackgroundInfluentialKapoor, P., Rajkumar, S. V., Dispenzieri, A. A., Gertz, M. A., Lacy, M. Q., Dingli, D., Mikhael, J. R., Roy, V., Kyle, R. A., Greipp, P. R., et al. (2011) · Leukemia · doi:10.1038/leu.2010.313 · Cited by 106
Chauhan, D., Ray, A., Viktorsson, K., Spira, J., Paba‐Prada, C. E., Munshi, N. C., Richardson, P. G. G., Lewensohn, R., & Anderson, K. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3752 · Cited by 107
Harousseau, J.-L., Palumbo, A., Richardson, P. G., Schlag, R., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Kentos, A., Cavo, M., Golenkov, A., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275800 · Cited by 105
Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., et al. (2008) · Blood · doi:10.1182/blood-2008-07-170746 · Cited by 108
Cornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 100
Multiple Myeloma: Charging Toward a Bright Future
Katzel, J. A., Hari, P., & Vesole, D. H. (2007) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.57.5.301 · Cited by 121
Hari, P. N., Zhang, M.-J., Roy, V, Pérez, W. S., Bashey, A., To, L. B., Elfenbein, G., Freytes, C. O., Gale, R. P., Gibson, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.61 · Cited by 100
How we manage autologous stem cell transplantation for patients with multiple myeloma
Gertz, M. A., & Dingli, D. (2014) · Blood · doi:10.1182/blood-2014-03-544759 · Cited by 106
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.